


Your health in the blink of an eye







50% OF GLAUCOMA NOT DIAGNOSED

3% of the population over 50 has glaucoma that lead to blindness

30% OF DIABETICS CAN BECOME BLIND

59 million diabetics in Europe need to screen for diabetic retinopathy every year

40% AT RISK OF BLINDNESS


If they don't see an ophthalmologist every year




PROBLEM



THE DISEASES






Diabetic Retinopathy (DR) is caused by uncontrolled blood sugar levels that damage retinal blood vessels

Glaucoma is an age related disease that damages your eye's optic nerve

THOSE CAN BE TREATED IF SCREENED EARLY

NOW



PATII OPHI OPHI OVER 6 mor 6 mor Pupil o after f Glauce

PATIENTS DISCOURAGED OPHTHALMOLOGISTS OVERWHELMED

- 6 months for an appointment
- Pupil dilatation : cannot drive after for 5 hours
- Glaucoma diagnostic : 1 hour

THE UTOPIA



SELF SCREENING No need of medical staff to take retinal pictures

NO APPOINTMENT

At the doorstep of the patient : diabetic clinics, GP, pharmacies


IMMEDIATE RESULT

Patients referred to the ophthalmologist on time if needed
















SCREENING WITH MONA KIOSK



Appointment



BUSINESS MODEL







3000 GPs and Pharmacies, > 5 million patients



22 000€ annually per kiosk



Direct sales force


Pay per patient : 18€, kiosk included

4000 diabetes clinics, >7 million patients

MARKET

Diabetics and >50: annual retinal screening








216M€

TAM 59 million diabetics 186 million >50

SAM Western Europe

SOM 12 million patients, 10% of SAM





Full solution

COMPETITIVE ADVANTAGES



MID

TERM


FIRST MOVER ADVANTAGE : BUSINESS MODEL AUTOMATED CAMERA LOCK IN CUSTOMERS WITH CAMERA LONG TERM LOAN CONTRACTS

GLAUCOMA SCREENING : IP CAMERA AUTOMATION

LONG TERM

REIMBURSEMENT LINKED TO THE SOLUTION CAPACITY TO INNOVATE: ALZHEIMER, DIABETES, CARDIOVASCULAR RISK SCREENING





VALUE PROPOSITION







Patient


Diabet.


Ophth.






















BEACHHEAD MARKET





New Teleophthalmology convention INAMI/RIZIV











GROWTH MARKETS






Existing reimbursement for DR screening 19€

12 million patients

ACHIEVEMENTS





MONA will be evaluated in 3 majors



SEED FUNDING : 0.7M€ TO 3 M€

	2021	2022	2023	2024	2025	2026
Revenue	158017	914017	3469850	9170833	14435833	19944000
COGS		177 350	534 936	1 308 926	1 970 971	2 728 571
Gross Marg.		578 650	2 633 064	7 718 074	12 321 029	17 215 429
Expenses	733 700	1 930 950	2 156 650	3 406 800	3 771 194	3 979 493
EBITDA	(575683)	(1194283)	778 264	4 455 107	8 693 669	13235 936

0.7MM€

Commercialization

Automate camera CE Mark 10 pilotes



1.7MM€

Expansion

Sales Force Diabetic Retinopathy Belgium and Germany



0.6MM€



Diversification

Glaucoma The Netherlands

THE TEAM



DR OLIVIER MÉNAGE CEO

PharmD, 25 years medical device experience in EMEA Abbott, Medtronic, Boston Scientific, J&J.



PR DR INGEBORG STALMANS

Chief Medical Officer

Ophthalmology Professor, Head of the Glaucoma Unit and Director of Ophthalmology Research Center, KUL





STEF ROMMES Deep Learning Engineer

Artificial Intelligence, Machine Learning developer at VITO Trained at VITO

TIMELINES

April 2021

August

2021

CE Mark

Automated camera

DR screening commercial launch **BNL** and Germany

January

2022

Glaucoma commercial launch

Commercial expansion





January 2024



MONATM



High social impact : prevent blindness

Experienced co-founders

Spin off: KUL and VITO



Seed funding ask 700 000€

Innovation : apply AI and robotics to eye screening







CONTACT US

Olivier Ménage

olivier.menage@vito.be

+32 470 912 972

https://mona.health/



MONATM